Novartis Lp(a) Therapy Falls Short in Phase 3 Trial on Cardiovascular Risk
TL;DR Summary
Novartis said pelacarsen lowered lipoprotein(a) but did not reduce the rate of heart attacks, strokes or other major cardiovascular events in the Phase 3 Lp(a)Horizon trial involving 8,323 high-risk patients; full topline results will be presented at a medical meeting, and analysts note deeper Lp(a) suppression or subpopulation effects might still matter for future efforts in this space.
- Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial Fierce Biotech
- The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists The New York Times
- Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal WSJ
- NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? Yahoo Finance
- Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Novartis
Reading Insights
Total Reads
1
Unique Readers
6
Time Saved
3 min
vs 4 min read
Condensed
91%
619 → 58 words
Want the full story? Read the original article
Read on Fierce Biotech